Letter to the Editor: Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people

Neurocase

Volumn 18, Issue 3, 2012, Pages 181-184

  Boot, Brendon P ^a   Partridge, Brad ^a,b   Hall, Wayne ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acetyl Cholinesterase Inhibitors; Cognitive Enhancement; Ethics; Neuroenhancement; Stimulants

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; OXYCODONE; SEROTONIN UPTAKE INHIBITOR; NOOTROPIC AGENT;

ARTICLE; ATTENTION; CHRONIC PAIN; CLINICAL PRACTICE; COGNITION; DEMENTIA; DEPRESSION; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EXECUTIVE FUNCTION; HUMAN; MEDICAL ETHICS; MEMORY; NEUROLOGIST; NONMALEFICENCE; PATIENT ASSESSMENT; PATIENT AUTONOMY; PATIENT COUNSELING; PRESCRIPTION; PUBLIC HEALTH; RISK ASSESSMENT; SLOW RELEASE FORMULATION; DRUG EFFECT; ETHICS; MEDICAL TECHNOLOGY; METHODOLOGY; NEUROLOGY; STANDARD;

BIOMEDICAL ENHANCEMENT; COGNITION; DRUG PRESCRIPTIONS; HUMANS; NEUROLOGY; NOOTROPIC AGENTS;

EID: 84861179584     PISSN: 13554794     EISSN: 14653656     Source Type: Journal    
DOI: 10.1080/13554794.2011.588174     Document Type: Article

References (12)

1. Banjo, O. C., Nadler, R. and Reiner, P. B. 2010. Physician attitudes towards pharmacological cognitive enhancement: Safety concerns are paramount. PloS One, 5(12): e14322
2. Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S. and Schaff, H. V. 1997. Valvular heart disease associated with fenfluramine-phentermine. NEJM, 337(9) Aug 28: 581-588.
3. Forlini, C. and Racine, E. 2009a. Disagreements with implications: Diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Medical Ethics, 10: 9
4. Forlini, C. and Racine, E. 2009b. Autonomy and coercion in academic 'cognitive enhancement' using methylphenidate: Perspectives of key stakeholders. Neurotics, 2: 163-177.
5. Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M.Campbell, P. 2008. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456(7223): 702-705.
6. Hall, W. and Degenhardt, L. 2007. Regulating opioid prescribing to provide access to effective treatment while minimising diversion: An overdue topic for research. Addiction, 102: 1685-1688.
7. Hotze, T. D., Shah, K., Anderson, E. E. and Wynia, M. K. 2011. 'Doctor, would you prescribe a pill to help me.?' A national survey of physicians on using medicine for human enhancement. AJOB, 11(1): 3-13.
8. Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J. and Johnson, B. T. 2008. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration. PLoS Medicine, 5(2): e45
9. Kushner, R. 1997. The treatment of obesity: A call for prudence and professionalism. Archives of Internal Medicine, 157(6): 602-604.
10. Larriviere, D., Williams, M. A., Rizzo, M. and Bonnie, R. J. 2009. Responding to requests from adult patients for neuroenhancements: Guidance of the Ethics, Law and Humanities Committee. Neurology, 73(17): 1406-1412.
11. Larriviere, D., Williams, M. A., Rizzo, M. and Bonnie, R. J. 2010. Reply from the authors. Neurology, 74: 1556
12. Racine, E. and Forlini, C. 2010. Responding to requests from adult patients for neuroenhancements. Neurology, 74: 1555